Loading...
Docoh
Log in Free sign up

Taro Pharmaceutical Industries (TARO)

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.

Company profile

Ticker
TARO
Exchange
NYSE
Website
www.taro.com
CEO
Uday Baldota
Employees
Location
Israel
Fiscal year end
Mar 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...
SEC CIK
0000906338
Corporate docs

TARO stock data

News

From Benzinga Pro
Taro Pharmaceutical Indus: Q1 Earnings Insights
27 Jul 22
Taro Pharmaceutical Indus (NYSE:TARO) reported its Q1 earnings results on Wednesday, July 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Taro Pharmaceutical Indus Q1 EPS $0.37 Down From $1.09 YoY, Sales $156.66M Up From $147.11M YoY
27 Jul 22
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.37 per share. This is a 66.06 percent decrease over earnings of $1.09 per share from the same period last year. The company reported $156.66
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
27 Jul 22
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For July 27, 2022
27 Jul 22
Stocks That Hit 52-Week Lows On Thursday
26 May 22

Press releases

From Benzinga Pro
Taro Provides Results for the Quarter Ended June 30, 2022
27 Jul 22
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter ended June 30, 2022. Quarter ended June 30, 2022* Highlights ─ compared to June
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2022
26 Jul 22
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2022, filed with the Securities and Exchange Commission (the "SEC"), is
Taro to Release First Quarter Results on July 27, 2022
26 Jul 22
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2022, after the close of market on Wednesday, July 27, 2022. The
Taro Provides Results for the Year Ended March 31, 2022
26 May 22
Taro to Announce Full Year Results on May 26, 2022
20 May 22

Calendar

25 Jul 22
13 Aug 22
31 Mar 23

Financial summary

Financial statements Chart TARO financial data
Quarter (USD) Mar 22 Mar 21 Mar 20 Mar 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Mar 22 Mar 21 Mar 20 Mar 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Financial data from company earnings reports.

Institutional ownership, Q1 2022

TARO institutional ownership history Ownership history
2.2% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 67 70 -4.3%
Opened positions 7 8 -12.5%
Closed positions 10 7 +42.9%
Increased positions 22 18 +22.2%
Reduced positions 27 30 -10.0%
13F shares Current Prev Q Change
Total value 198.49M 655.91M -69.7%
Total shares 4.48M 4.62M -2.9%
Total puts 1K 0 NEW
Total calls 400 0 NEW
Total put/call ratio 2.5 – –
Largest owners Shares Value Change
Renaissance Technologies 678.3K $29.34M -2.5%
Krensavage Asset Management 565.95K $24.48M +5.0%
Dimensional Fund Advisors 534.63K $23.13M +3.5%
Brandes Investment Partners 379.32K $16.41M +8.5%
Acadian Asset Management 326.43K $14.09M -4.1%
FMR 320.06K $13.85M -28.1%
IVZ Invesco 231.5K $10.01M -15.7%
AMP Ameriprise Financial 222.84K $9.64M +47.2%
Eversept Partners 220.29K $9.53M +21.6%
Hotchkis & Wiley Capital Management 191.82K $8.3M +22.2%
Largest transactions Shares Bought/sold Change
FMR 320.06K -125.22K -28.1%
AMP Ameriprise Financial 222.84K +71.49K +47.2%
Norges Bank 0 -60.79K EXIT
NTRS Northern Trust 20.94K -51.34K -71.0%
IVZ Invesco 231.5K -43.16K -15.7%
Eversept Partners 220.29K +39.14K +21.6%
Hotchkis & Wiley Capital Management 191.82K +34.8K +22.2%
Brandes Investment Partners 379.32K +29.61K +8.5%
Krensavage Asset Management 565.95K +26.98K +5.0%
Dimensional Fund Advisors 534.63K +17.95K +3.5%
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Akorn • Teligent

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: acne, adulterated, Alchemee, anti, argued, assembled, attrition, authoritative, beautify, Biden, bifurcated, Bill, Bowne, CAL, card, chair, Chapter, CIT, clause, Clawback, cleanse, clearance, conclusion, condensed, Congressional, contempt, contrary, Coote, CSA, defective, Delaware, Differin, DPP, eager, endeavor, entirety, EPS, fact, faster, fifty, freestanding, FTC, gas, geopolitical, GRASE, greenhouse, heighten, Herzlya, host, inactive, inconsistency, inconsistent, indemnity, inferior, influential, injured, insufficient, intensification, Interbank, Japan, Kingdom, KK, layer, LLC, logistic, London, lost, Lynch, macroeconomic, magazine, MEEM, merchandise, merchant, Merrill, Mifalot, Minister, misbranded, MONETA, monograph, NADAC, necessitate, neoplastic, oassessing, odetermining, orecommending, override, Oxymetazoline, parallel, persuade, plaintiff, pose, posture, preemption, premarket, Proactiv, Proactive, ProactivMD, proceed, profession, proper, provisional, Prudential, quickly, randomized, Realty, recapture, recession, Reichman, rulemaking, Russia, Safer, shortage, skincare, slowdown, stolen, Sulfate, sunscreen, Suprep, survey, tangible, Task, Template, text, Today, TPC, transparency, transparent, trapped, Treasurer, Ukraine, unfair, unlawful, unsafe, unusable, unwilling, vaccinated, Vicept, voluntarily, wage, waive, war, William, yield, YK
Removed: aa, advertise, advertised, advocacy, Analytical, API, Attestation, Avi, Avramoff, cancellation, cancelled, competence, consolidating, decide, feedback, FX, geographical, Herzliya, IDC, Imiquimod, instruct, Interdisciplinary, Itamar, Ivermectin, Karsenti, LLP, Magistrate, MBA, Michele, Micro, obligated, OSD, penned, Pertinent, Pharmacokinetic, Pharmacovigilance, preclude, preference, Princeton, progressively, promoted, QUANTITATIVE, ratified, reconsidered, recoverability, repeal, Secretary, Stern, Sulf, TDC, terminate, TIMETABLE, UNRESOLVED, Visosky, worked
From filing 20-F 2022 FY
Financial reports
View all
20-F
2022 FY
Annual report (foreign)
25 Jul 22
20-F
2021 FY
Annual report (foreign)
17 Jun 21
20-F
2020 FY
Annual report (foreign)
19 Jun 20
20-F
2019 FY
Annual report (foreign)
20 Jun 19
20-F
2018 FY
Annual report (foreign)
21 Jun 18
20-F
2017 FY
Annual report (foreign)
20 Jun 17
20-F
2016 FY
Annual report (foreign)
8 Jun 16
20-F
2015 FY
Annual report (foreign)
30 Jun 15
20-F
2014 FY
Annual report (foreign)
2 Jul 14
20-F
2013 FY
Annual report (foreign)
1 Jul 13
Current reports
View all
6-K
Current report (foreign)
28 Jul 22
6-K
Current report (foreign)
27 May 22
6-K
Current report (foreign)
28 Feb 22
6-K
Current report (foreign)
22 Feb 22
6-K
Current report (foreign)
27 Jan 22
6-K
Current report (foreign)
17 Dec 21
6-K
Current report (foreign)
1 Dec 21
6-K
Current report (foreign)
5 Nov 21
6-K
Current report (foreign)
4 Nov 21
6-K
Current report (foreign)
28 Oct 21
Registration and prospectus
View all
SC TO-I/A
Issuer tender offer statement (amended)
19 Dec 19
SC TO-I/A
Issuer tender offer statement (amended)
17 Dec 19
SC TO-I/A
Issuer tender offer statement (amended)
3 Dec 19
SC TO-I
Issuer tender offer statement
15 Nov 19
SC TO-I/A
Issuer tender offer statement (amended)
29 Dec 13
SC TO-I/A
Issuer tender offer statement (amended)
23 Dec 13
SC TO-I/A
Issuer tender offer statement (amended)
11 Dec 13
SC TO-I/A
Issuer tender offer statement (amended)
8 Dec 13
SC TO-I
Issuer tender offer statement
24 Nov 13
SC 13E3/A
Going private transaction (amended)
7 Feb 13
Proxies
No filings
Other
View all
CORRESP
Correspondence with SEC
14 May 20
UPLOAD
Letter from SEC
14 May 20
UPLOAD
Letter from SEC
6 May 20
CORRESP
Correspondence with SEC
9 Apr 20
UPLOAD
Letter from SEC
2 Mar 20
CORRESP
Correspondence with SEC
19 Feb 20
UPLOAD
Letter from SEC
20 Jan 20
CORRESP
Correspondence with SEC
2 Dec 19
UPLOAD
Letter from SEC
24 Nov 19
UPLOAD
Letter from SEC
23 Aug 15
Ownership
View all
SC 13D/A
Taro Pharmaceutical Industries LTD
26 Nov 13
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
7 Feb 13
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
12 Aug 12
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
17 Oct 11
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
18 Jan 11
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / FRANKLIN RESOURCES ownership change
7 Nov 10
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
3 Nov 10
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
4 Oct 10
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
23 Sep 10
SC 13D/A
TARO PHARMACEUTICAL INDUSTRIES / SUN PHARMACEUTICAL INDUSTRIES ownership change
9 Sep 10

Patents

View all
Utility
Stable Topical Compositions of Fenoldopam
10 Feb 22
The present disclosure is directed to a topical composition, e.g., a physically and chemically stable topical composition of Fenoldopam comprising about 0.1% to about 5% by weight of Fenoldopam or a pharmaceutically acceptable salt thereof, at least one polyacrylamide-type gelling agent, at least one cellulose-type gelling agent, and at least one solvent, wherein the Fenoldopam is substantially solubilized in the composition, and wherein the composition is stable for at least twelve months at 25° C. and 60% relative humidity.
Utility
Topical Montelukast Formulations
20 Jan 22
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.
Utility
Topical Montelukast Formulations
23 Dec 21
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.
Utility
Topical Montelukast formulations
16 Nov 21
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 μm, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.
Utility
Topical Montelukast Formulations
5 Aug 21
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 μm, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.

Transcripts

2021 Q2
Earnings call transcript
31 Oct 20

Reddit threads

View all